Fraud Claims Cut From Actimmune Marketing MDL
A federal judge has dismissed fraud claims from a suit brought by a putative class of patients and Zurich Insurance Co. alleging that biotechnology company InterMune Inc. fraudulently promoted its drug...To view the full article, register now.
Already a subscriber? Click here to view full article